We incorporated several neuroimaging-derived measures sensitive to PD progression51, from structural MRI-based gray matter density (GM) and dendrite density (t1/t2 ratio), diffusion-based measures of microstructural integrity (MD and FA)52, functional neuronal activity (fALFF) and presynaptic dopamine transporter availability (DAT-SPECT). The gene discussed is SLC6A3; the disease is Parkinson disease.